Author Affiliations: Deutsches Herzzentrum, Technische Universität, Munich, Germany.
Cardiogenic shock complicating acute myocardial infarction (AMI) is one of the most serious and challenging conditions in cardiovascular medicine, with up to two thirds of patients dying within a few weeks.1,2 According to data from a national registry of nearly 300 000 patients with ST-segment elevation AMI, the overall incidence of cardiogenic shock (diagnosed at both presentation and after admission) was 8.6%.3
Ndrepepa G, Schömig A, Kastrati A. Lack of Benefit From Nitric Oxide Synthase Inhibition in Patients With Cardiogenic ShockLooking for the Reasons. JAMA. 2007;297(15):1711-1713. doi:10.1001/jama.297.15.1711